Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| The role of systemic inflammation in hepatic encephalopathy: advances… Rifaximin · PMID 41904644 | Maladie de Parkinson | Immunomodulation | Publication | PubMed | Voir la publication source This review synthesizes current evidence establishing systemic inflammation as a key pathogenic driver in hepatic encep… | Annals of medicine 2026-08-16 13:06:29 | Source |
| Differential modulation of gentamicin antibacterial activity by vitam… Vitamin D3 · PMID 42035400 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Antimicrobial resistance and gentamicin-associated toxicity necessitate the development of non-antibiotic adjuvants tha… | Annals of medicine 2026-08-16 13:06:28 | Source |
| Effects of vitamin D supplementation on cardiac, muscle, and immune r… Vitamin D3 · PMID 41966073 | Maladie de Parkinson | Neuroprotection | Publication | PubMed | Voir la publication source Strenuous endurance exercise imposes substantial physiological stress on the cardiovascular system and has been associa… | Journal of the International Society of Sports Nutriti… 2026-08-16 13:06:28 | Source |
| Metabolomic analysis of follicular fluid in women with unexplained in… Vitamin D3 · PMID 41793761 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Unexplained infertility (UI) affects ∼10% of infertile couples, yet standard diagnostic protocols fail to identify a ca… | Systems biology in reproductive medicine 2026-08-16 13:06:28 | Source |
| A phase IIb, randomised, double-blind, placebo-controlled, dose-rangi… NTCELL Implantation · PMID 30503748 | Maladie de Parkinson | Remyélinisation indirecte / réparation · Neuroprotection | Publication | PubMed | Voir la publication source Regenerative therapies in Parkinson's disease aim to slow neurodegeneration and re-establish damaged neuronal circuitry… | Parkinsonism & related disorders 2026-08-16 13:06:27 | Source |
| Randomized Controlled Trial Evaluating Rotigotine Safety in PKD. Rotigotine · PMID 42542571 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Résumé non disponible dans la base locale. | Kidney international reports 2026-08-16 13:06:25 | Source |
| Study on dichloromethane content measurement of the preparation proce… Rotigotine · PMID 42462556 | Maladie de Parkinson | Thérapie génique | Publication | PubMed | Voir la publication source Microsphere formulations are extensively investigated as innovative drug delivery systems. Given their intricate formul… | Spectrochimica acta. Part A, Molecular and biomolecula… 2026-08-16 13:06:25 | Source |
| Between reality and meaning: a qualitative study on virtual reality a… Intervention with virtual reality · PMID 42093209 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Virtual reality (VR) is increasingly recognized as a supportive tool in palliative care due to its potential to promote… | International journal of qualitative studies on health… 2026-08-16 13:06:24 | Source |
| Exploring school nurses' experiences of a metaverse-based infectious… Intervention with virtual reality · PMID 41874230 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source This study aimed to explore school nurses' experiences and perceptions of metaverse-based simulation training (MBST) fo… | International journal of qualitative studies on health… 2026-08-16 13:06:24 | Source |
| Isolating Eye-Movement Artifacts from EEG Signals. Intervention with virtual reality · PMID 42175605 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source The electroencephalogram (EEG) provides a direct measure of brain electrical activity but is typically contaminated by… | International journal of neural systems 2026-08-16 13:06:24 | Source |
| Duration of "Good On" time per dose: Immediate-release carbidopa-levo… IR CD-LD · PMID 39733558 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source For Parkinson's disease patients with motor fluctuations, the duration of benefit per levodopa dose is a key metric tha… | Parkinsonism & related disorders 2026-08-16 13:06:23 | Source |
| Randomized trial of IPX066, carbidopa/levodopa extended release, in e… IPX066 · PMID 24055014 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source IPX066 is an extended release carbidopa/levodopa formulation designed to rapidly attain and maintain therapeutic plasma… | Parkinsonism & related disorders 2026-08-16 13:06:22 | Source |
| The Effects of Adapted Tango on Dynamic Balance and Dual-Task Perform… Investigation of Dual-Task Exercise's Effect in Parkinson's Disease · PMID 41194589 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source This study investigated the effects of Adapted Tango (AT) on dynamic balance, dual-tasking, and leg muscle antagonist a… | Journal of motor behavior 2026-08-16 13:06:21 | Source |
| Biological mechanisms of different exercise modalities in improving s… Aerobic exercise · PMID 42592515 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source Sleep disorders such as insomnia, sleep apnea, and circadian rhythm dysfunctions constitute a major public health chall… | IBRO neuroscience reports 2026-08-16 13:06:18 | Source |
| Effects of different caffeine doses on fat oxidation and cardiovascul… Aerobic exercise · PMID 42120324 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source This study examined the acute effects of different caffeine doses on fat oxidation and cardiovascular responses at rest… | Journal of the International Society of Sports Nutriti… 2026-08-16 13:06:18 | Source |
| The combined effect of L-arginine and Vitamin C supplementation on ni… Aerobic exercise · PMID 42433304 | Maladie de Parkinson | À vérifier | Publication | PubMed | Voir la publication source This study aimed to investigate the effects of combined L-arginine and Vitamin C supplementation on nitrogen balance, b… | Journal of diabetes and metabolic disorders 2026-08-16 13:06:18 | Source |
| Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Pro… liposomal doxorubicin · PMID 42503863 | Cancer · Maladie de Parkinson · Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Clinical translation of nanomedicines is greatly hindered by insufficient understanding of their in vivo process, yet a… | ACS nano 2026-08-16 13:06:12 | Source |
| Exploiting the dynamics of hyperthermia-enhanced delivery of thermose… liposomal doxorubicin · PMID 42108654 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Thermosensitive liposomal (TSL) drug delivery with intravascular release under hyperthermia is a promising approach for… | Drug delivery 2026-08-16 13:06:12 | Source |
| Heat-activated intravenous liposomal doxorubicin combined with mitomy… liposomal doxorubicin · PMID 41631502 | Cancer | Traitement symptomatique | Publication | PubMed | Voir la publication source To evaluate the safety and pharmacokinetics of lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) combined wi… | International journal of hyperthermia : the official j… 2026-08-16 13:06:12 | Source |
| Integrating spectrum-effect relationship, network pharmacology and mu… Doxorubicin · PMID 42492702 | Cancer · Maladie de Parkinson | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Cybister chinensis Motschulsky is a traditional Chinese medicinal insect traditionally used to tonify the kidney, and c… | Journal of ethnopharmacology 2026-08-16 13:06:09 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||